1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Isofol Medical AB (publ)
  6. News
  7. Summary
    ISOFOL   SE0009581051

ISOFOL MEDICAL AB (PUBL)

(ISOFOL)
  Report
Delayed Nasdaq Stockholm  -  05/20 11:29:39 am EDT
9.250 SEK   +3.58%
05/19Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19, 2022
AQ
05/19Isofol Medical AB Approves Board Changes
CI
05/16DNB MARKETS - ISOFOL MEDICAL :  Approaching AGENT read-out
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Isofol Medical : – Company Presentation >>

12/08/2021 | 09:52am EDT

December 2021

Setting the stage for arfolitixorin's market launch

-planned for 2023

© ISOFOL MEDICAL AB (publ)

Disclaimer

This company presentation of Isofol Medical AB (publ) ("Isofol") has been prepared for advertisement purposes. It is not a prospectus and has not been prepared in accordance with the prospectus requirements in the Swedish Financial Instruments Trading Act (lagen (1991:980) om handel med finansiella instrument) or the European prospectus regulation (809/2004/EC) (the "Prospectus Regulations"). This company presentation is not subject to any registration or approval requirements under the Prospectus Regulations and has not been, and will not be, examined, approved or registered by the Swedish Financial Supervisory Authority or any financial supervisory authority or other supervisory body within the EU.

The company presentation may not be forwarded, reproduced or made available in or into any jurisdiction in which such publication or distribution would require any additional documentation to be prepared or registration effected or that any measures are taken in addition to those required under Swedish law or where it would be in conflict with any law or regulation in such jurisdiction. Persons who come into possession of this document are required to inform themselves about, and to observe, such restrictions.

The courts of Sweden shall have exclusive jurisdiction over any dispute arising out of or in connection with this document company presentation and the City Court of Gothenburg, Sweden, shall be the court of first instance.

© ISOFOL MEDICAL AB (publ)

2

Isofol at a glance

Isofol was founded in 2008 in Gothenburg, secured funding of an additional MSEK 452 in June 2021 and listed on Nasdaq Stockholm in October 2021

Isofol develops arfolitixorin for the treatment of colorectal cancer (CRC), the third most common cancer type

Since 2013 Isofol have strategic CMC partnerships with Merck & Cie and Recipharm

Isofol has two strategic licensing agreements from 2020 with Solasia Pharma KK in Japan and Endo/Paladin in Canada

Late stage fully recruited phase III study with Top-Line results estimated during H1 2022

Pre-commercialization activities initiated, including the development of medical affairs and commercial launch packages

Shareholders

Number of

Capital/Votes

shares

(%)

Futur Pension

13,335,256

8.26%

Avanza Pension

7,927,068

4.91%

Handelsbanken Fonder

5,938,471

3.68%

Nordnet Pensionsförsäkring

5,433,172

3.36%

Swedbank Försäkring

5,268,567

3.26%

Hans Enocson

4,555,236

2.82%

Fjärde AP-fonden

4,521,257

2.80%

Swedbank Robur Fonder

4,175,839

2.59%

Bengt Gustafsson*

3,749,459

2.32%

Peak Asset Management

3,381,964

2.09%

10 larges share owners

58,286,289

36.09%

Other owners

103,229,111

63.91%

TOTAL

161,151,440

100%

Number of shareholders approx. 4500

Source: The list of Isofol´s largest shareholders is based on information from Euroclear Sweden AB as of 30 September 2021. * Own or related natural or legal person holding shares (direct and indirect) and other financial instruments in the company

© ISOFOL MEDICAL AB (publ)

3

Colorectal cancer (CRC) - Large and underserved segment

3rd most common and 2nd deadliest cancer with an urgent large unmet need

COLORECTAL CANCER FACTSHEET

Colorectal cancer is the third most common cancer1

10% of cancers discovered annually are colorectal cancer

(millions)

2,4

12%

11%

10%

2,2

2,0

incidence

1,8

7%

1,6

5%

1,2

1,4

6%

global

1,0

0,8

Annual

0,6

0,4

0,2

0,0

Lung

Breast Colorectal Prostate Stomach

Liver

1.9M 1.9M people are diagnosed with CRC each year globally1

10 The 5-year survival rate for patients % with stage 4 colorectal cancer (mCRC)

falls to around 10%2

GROWING INCIDENCE

>60% The global burden of CRC is expected to increase by over 60% from 1.9M 2020 cases to 3.1M in 20401

GLOBAL CRC MARKET $10.6B IN 2028

Total market size will grow ~$3B from 2018 to 20282

10.6

7.5

2028

2018

© ISOFOL MEDICAL AB (publ)

Source: 1)

GLOBOCAN 2020, Cancer Incidence and Mortality Worldwide

4

2)

GlobalData 2020

Strategic priorities - Paving the way for success

Strategic priorities

1 Finalizing the global phase III AGENT study

2 Continue to execute on strategic partnerships in Japan and Canada

3 Evaluate partnering options

4 Build arfolitixorin awareness and value through accelerated pre-commercialization activities

© ISOFOL MEDICAL AB (publ)

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Isofol Medical AB published this content on 08 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 December 2021 14:51:02 UTC.


© Publicnow 2021
All news about ISOFOL MEDICAL AB (PUBL)
05/19Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19, 2022
AQ
05/19Isofol Medical AB Approves Board Changes
CI
05/16DNB MARKETS - ISOFOL MEDICAL :  Approaching AGENT read-out
AQ
05/12Isofol Medical AB (publ) publishes interim report, January-March 2022
AQ
05/03Invitation to presentation of Isofol's report for the first quarter of 2022
AQ
04/27ISOFOL MEDICAL : Annual Report 2021 (English)
PU
04/27Isofol Medical AB (publ) publishes annual report and corporate governance report for 20..
AQ
04/22Isofol announces start of study data analysis of phase III AGENT study in advanced meta..
AQ
04/22Isofol Announces Start of Study Data Analysis of Phase III Agent Study in Advanced Meta..
CI
04/12ISOFOL MEDICAL : The nomination_committees_proposals (English)
PU
More news
Financials
Sales 2022 76,4 M 7,67 M 7,67 M
Net income 2022 -209 M -20,9 M -20,9 M
Net cash 2022 242 M 24,3 M 24,3 M
P/E ratio 2022 -7,15x
Yield 2022 -
Capitalization 1 494 M 150 M 150 M
EV / Sales 2022 16,4x
EV / Sales 2023 4,40x
Nbr of Employees 15
Free-Float 80,7%
Chart ISOFOL MEDICAL AB (PUBL)
Duration : Period :
Isofol Medical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ISOFOL MEDICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 9,25 SEK
Average target price 23,50 SEK
Spread / Average Target 154%
EPS Revisions
Managers and Directors
Jarl Ulf Birger Jungnelius Chief Executive Officer
Gustaf Albért Chief Financial Officer
Pär-Ola Mannefred Chairman
Roger Tell Chief Medical Officer
Paula S. Sjovall Boultbee Director
Sector and Competitors
1st jan.Capi. (M$)
ISOFOL MEDICAL AB (PUBL)0.11%150
MERCK KGAA-24.05%79 076
KYOWA KIRIN CO. LTD.-13.65%11 377
SK BIOPHARMACEUTICALS CO., LTD.-11.21%5 308
YUHAN CORPORATION-5.80%3 126
BETTA PHARMACEUTICALS CO., LTD.-43.32%2 808